MedTrace Logo

Subcuteous Methotrexate in Rheumatoid Arthritis

NCT07094880 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-07-30

No results posted yet for this study

Summary

Methotrexate use is important for the treatment of Rheumatoid arthritis. Some patients can not tolerate oral methotrexate. So subcutaneous may help to overcome it.

Conditions

  • Methotrexate Adverse Reaction
  • Advantage of Using Subcutaneous Route for Methotrexate

Interventions

DRUG

Tab. Methotrexate 25mg/week

Tab. Methotrexate will be given orally in one arm at a dose of 25 mg/week

DRUG

Inj. Methotrexate 25mg/week

Inj. Methotrexate 25 mg/week will be given subcutaneously in another arm

Sponsors & Collaborators

  • Bangladesh Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2016-06-01
Completion
2016-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07094880 on ClinicalTrials.gov